Login to Your Account

CTI Biopharma clears path to key pacritinib meeting with FDA

By Michael Fitzhugh
Staff Writer

Monday, August 29, 2016

Top-line data from CTI Biopharma Corp.'s phase III trial of pacritinib, a JAK2/FLT3 multikinase inhibitor for high-risk patients with advanced myelofibrosis showed the treatment demonstrated statistically significant improvement in spleen volume reduction vs. best available treatment.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription